SPOTLIGHT: Medicaid spends big bucks on antipsychotics for elderly

Medicaid spends more money on antipsychotics than on any other class of drugs. That's partly because nursing homes depend on these drugs to quiet patients with dementia, a use that isn't approved by the FDA--in fact, is warned against because of the risk of severe side effects. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.